China Biotech Services Holdings Ltd, formerly Rui Kang Pharmaceutical Group Investments Ltd, is an investment holding company principally engaged in the provision of medical health check services. The Company operates its business through six segments. The Medical and Health Related Services segment provides medical laboratory testing services and health check services. The Insurance Brokerage segment is engaged in the provision of brokerage services. The Immunotherapy segment provides tumor immune call therapy, immune cell storage and health management services. The Pharmaceutical Products segment is engaged in the manufacture, research and development, sale and distribution of health related and pharmaceutical products. The Securities segment is engaged in the trading of securities. The Others segment is engaged in the money lending business and provision of logistic services.

Employees

142

Sector

Healthcare Facilities & Services

More about the company

Quotes

Date	Price	Change	Volume
18/06/26	0.6000 $	+17.65%	295,000
17/06/26	0.5100 $	0.00%	170,000
16/06/26	0.5100 $	+2.00%	185,000
15/06/26	0.5000 $	+6.38%	300,000
12/06/26	0.4700 $	+4.44%	195,000

Delayed Quote Hong Kong S.E.

More quotes

Income Statement and Estimates

More financial data

Market Closed - Hong Kong S.E. Other stock markets 12:08:08 18/06/2026 +04			5-day change	1st Jan Change
0.6000 ^HKD	+17.65%		+22.45%	-24.05%

05-18	China Biotech Services' unit disposes entire stake in PHC Medical Diagnostic Centre, others	RE
04-30	China Biotech Services says He Xun resigns as executive director	RE

Market Cap	585M 74.7M 65.22M 60.06M 56.54M 106M 7.05B 107M 715M 277M 3.47B 280M 274M 12.05B	P/E 2024	-2.49x	P/E 2025	-11.2x
Enterprise Value	968M 124M 108M 99.33M 93.51M 175M 11.65B 176M 1.18B 459M 5.74B 464M 454M 19.93B	EV / Sales 2024	9.45x	EV / Sales 2025	15.7x
Free-Float	35.46%	Yield 2024 *	-	Yield 2025	-

05-18	China Biotech Services' unit disposes entire stake in PHC Medical Diagnostic Centre, others	RE
04-30	China Biotech Services says He Xun resigns as executive director	RE
04-30	China Biotech Services Holdings Limited Announces Resignation He Xun as Executive Director, Effective May 1, 2026	CI
04-29	China Biotech Services Holdings Limited Auditor Raises 'Going Concern' Doubt	CI
03-27	China Biotech Services Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-06	China Biotech Services expects FY net loss of not more than HK$100 million	RE
03-06	China Biotech Services Holdings Limited Provides Consolidated Earnings Guidance for the Year Ended 31 December 2025	CI
02-20	China Biotech Services Holdings Limited announced that it has received HKD 272.3 million in funding from Wealth Strategy Holding Ltd	CI
12-30	China Biotech Services to issue convertible bonds	RE
12-29	China Biotech Services Holdings Limited announced that it expects to receive HKD 272.3 million in funding	CI
29/09/25	China Biotech Services says outstanding convertible bonds amount to $6 million	RE
11/09/25	China Biotech Services' unit enters loan contract with Hainan Rural Commercial Bank	RE
28/08/25	China Biotech Services Holdings Limited Reports Earnings Results for the Half Year Ended June 30, 2025	CI

10/01/23	China Biotech Services subsidiary AMDL nominated as Top Clinical Laboratory Services Company in APAC 2022 and receives CAP Accreditation Certificate	AQ
24/06/22	Sumitomo Heavy Industries, Ltd. - Notice Regarding Our First Overseas Introduction of BNCT in the Hainan Medical Tourism Pilot Zone, China	AQ
10/08/21	China Biotech Services : AMDL, a Subsidiary of China Biotech Services, is Exclusively Licensed to Distribute FDA Approved Lung & Colon Cancer Companion Diagnostic Assay in Several Asian Regions Including China	AQ
28/06/21	China Biotech Services (8037.HK): Confident shareholders are taking long on their books in anticipation of promising results to be generated from the double engines of growth on cell therapy and precision diagnostic businesses	AQ
29/01/21	China Biotech Services : Shanghai Longyao Chief Scientist Professor Xuanming Yang published a research article on optimizing CAR-T cells function with independently expressed full-length OX40	AQ

China Biotech Services Holdings Limited Stock

Stocks

8037

BMG2152F1014

Healthcare Facilities & Services

Valuation: China Biotech Services Holdings Limited

Chart: China Biotech Services Holdings Limited

Latest news : China Biotech Services Holdings Limited

Press Releases: China Biotech Services Holdings Limited

Quotes and Performance

Course Extremes

Managers and Directors: China Biotech Services Holdings Limited

Latest insider transactions

Other Healthcare Facilities & Services

Financials

Company Profile

Quotes

Income Statement and Estimates

1 day	+17.65%
1 week	+22.45%
1 month	-4.76%
3 months	-10.45%
6 months	-33.33%
Current year	-24.05%

1 week	0.43	0.6
1 month	0.43	0.66
Current year	0.43	0.92
1 year	0.43	1.33
3 years	0.25	1.33
5 years	0.25	2.64
10 years	0.16	2.64

Manager	Title	Age	Since
Eddy Lai DFI	Director of Finance/CFO	-	-
Xiao Lin Liu CMP	Compliance Officer	55	26/05/2022
Xuan ming Yang CTO	Chief Tech/Sci/R&D Officer	-	-

Director	Title	Age	Since
Guo Xiang Yan BRD	Director/Board Member	60	07/08/2017
Song Huang BRD	Director/Board Member	44	15/09/2017
Xiao Lin Liu CHM	Chairman	55	28/08/2017

Date	Insider	Type	Main position	Quantity	% Market Cap.
03-30	Xiao Lin Liu	Other	Chairman	3,600,000	0.3690%
02/09/24	Xun He	Other	Director	3,220,000	0.3300%
13/06/24	Hoi Yam Chui	Other	Director	5,000,000	0.5191%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CHINA BIOTECH SERVICES HOLDINGS LIMITED	+17.65%	+22.45%	-18.92%	-40.00%	63.51M
CVS HEALTH CORPORATION	-0.85%	+0.31%	+46.55%	+45.19%	127B
HCA HEALTHCARE, INC.	-3.35%	+0.49%	+0.73%	+29.33%	86.11B
FRESENIUS SE & CO. KGAA	+0.69%	+4.30%	-8.60%	+52.01%	25.49B
QUEST DIAGNOSTICS INCORPORATED	-1.40%	-4.31%	+8.97%	+40.69%	21.89B
LABCORP HOLDINGS INC.	-1.44%	-4.77%	-1.40%	+9.20%	21.28B
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	+0.05%	+1.63%	-10.98%	-20.81%	20.33B
TENET HEALTHCARE CORPORATION	-3.32%	+4.73%	+3.05%	+120.03%	15.38B
REDE D'OR SÃO LUIZ S.A.	+0.39%	-2.32%	-5.73%	-0.60%	14.4B
DAVITA INC.	-1.27%	+4.72%	+52.30%	+112.98%	13.52B
Average	+0.71%	+2.43%	+6.60%	+34.80%	34.5B
Weighted average by Cap.	-1.45%	+2.07%	+18.40%	+39.41%

	2024	2025
Net sales	70.51M 9M 7.86M 7.23M 6.81M 12.71M 849M 12.83M 86.08M 33.41M 418M 33.77M 33.04M 1.45B	73.5M 9.38M 8.19M 7.54M 7.1M 13.25M 885M 13.37M 89.73M 34.83M 435M 35.2M 34.45M 1.51B
Net income	-198M -25.28M -22.08M -20.33M -19.14M -35.72M -2.38B -36.05M -242M -93.88M -1.17B -94.9M -92.86M -4.08B	-68.78M -8.78M -7.66M -7.06M -6.64M -12.4M -828M -12.51M -83.96M -32.59M -407M -32.94M -32.23M -1.42B
Net Debt	169M 21.55M 18.82M 17.33M 16.31M 30.45M 2.03B 30.73M 206M 80.03M 1B 80.9M 79.17M 3.48B	383M 48.85M 42.65M 39.27M 36.97M 69.01M 4.61B 69.65M 467M 181M 2.27B 183M 179M 7.88B